SCHEMBL543777

SCHEMBL543777

NC(=O)N(S)c1cccc(Nc2ncco2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38
CSNK2A1 P68400 1/20 0.38
CSNK2A3 Q8NEV1 1/20 0.38
ROCK1 Q13464 2/20 0.36
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PSMD14 O00487 1/20 0.34
STAMBP O95630 1/20 0.34
COPS5 Q92905 1/20 0.34
LMNA P02545 1/20 0.33
AURKA O14965 3/20 0.33
MAPK8 P45983 1/20 0.32
PIK3CG P48736 1/20 0.32
GSK3B P49841 1/20 0.32
CAMKK2 Q96RR4 1/20 0.32
NAMPT P43490 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
RAF1 P04049 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL544521 0.78 KIF11 (0.45) CSNK2A2CSNK2BCSNK2A1CSNK2A3ROCK1
SCHEMBL544461 0.74 AURKA (0.54) CSNK2A2CSNK2BCSNK2A1CSNK2A3ROCK1
SCHEMBL543837 0.73 HDAC3 (0.42) CSNK2A2CSNK2BCSNK2A1CSNK2A3MAPT
SCHEMBL544110 0.73 NPC1 (0.44) CSNK2A2CSNK2BCSNK2A1CSNK2A3ROCK1
SCHEMBL544111 0.72 MEN1 (0.50) ROCK1MAPTLMNA
SCHEMBL543776 0.72 KMT2A (0.47) CSNK2A2CSNK2BCSNK2A1CSNK2A3ROCK1
SCHEMBL543690 0.69 ROCK1 (0.58) ROCK1MAPT
SCHEMBL4532117 0.69 EGFR (0.50) AURKA
SCHEMBL729232 0.68 FLT1 (0.46) CSNK2A1ROCK1MAPTSMN1; SMN2AURKA
SCHEMBL6237657 0.67 AURKA (0.57) MAPTSMN1; SMN2LMNAAURKARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110591-B2 2-aminoaryloxazole compounds as tyrosine kinase inhibitors AB SCIENCE (FR) 2012-02-07 US disclosed
US-7718676-B2 E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection AB SCIENCE (FR) 2010-05-18 US disclosed
US-20100113471-A1 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors AB SCIENCE 2010-05-06 US disclosed
EP-1684750-B1 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2010-04-28 EP disclosed
US-20070142390-A1 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors AB SCIENCE 2007-06-21 US disclosed
EP-1684750-A2 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS AB Science (FR) 2006-08-02 EP disclosed
WO-2005040139-A2 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142390-A1 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors FGFR3, ABL1, FLT3 CSNK2A2 835/4885CSNK2B 880/4885CSNK2A1 886/4885
US-20100113471-A1 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors FGFR3, FLT3, ABL1 CSNK2A2 1120/4885CSNK2B 1352/4885CSNK2A1 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.